CD31 Antibody Market was valued at USD 0.45 Billion in 2022 and is projected to reach USD 0.68 Billion by 2030, growing at a CAGR of 6.8% from 2024 to 2030.
The global CD31 antibody market is experiencing steady growth due to increasing applications in biomedical research, diagnostics, and therapeutics. CD31, also known as platelet endothelial cell adhesion molecule 1 PECAM 1, is an essential marker for endothelial cells and plays a significant role in cell cell adhesion. The market size of CD31 antibodies was valued at approximately USD 450 million in 2023 and is projected to grow at a compound annual growth rate CAGR of 5.8% over the next 5 10 years, reaching an estimated value of USD 800 million by 2033.
Several factors are driving this market's growth, including the rising prevalence of cardiovascular diseases, cancer, and autoimmune disorders, where CD31 plays a key role in cell signaling and endothelial function. Additionally, advancements in biotechnology, such as the development of monoclonal antibodies, and increasing demand for personalized medicine and immunotherapies are expected to contribute to the market’s expansion.
Get an In-Depth Research Analysis of the Global CD31 Antibody Market Size And Forecast [2025-2032]
Increased Research Investment: Governments, pharmaceutical companies, and research institutions are investing heavily in studies related to immunology, oncology, and cardiovascular diseases, where CD31 antibodies are critical tools for analyzing cell interactions.
Rising Incidence of Cardiovascular Diseases and Cancer: As the prevalence of these diseases increases globally, there is a growing demand for diagnostic and therapeutic antibodies, including CD31 antibodies, for disease detection and treatment.
Technological Advancements in Antibody Production: The development of monoclonal antibodies and more precise production techniques, such as recombinant antibody technologies, are facilitating higher production efficiency and better targeting of specific diseases.
High Cost of Antibody Production: The production of high quality, specific antibodies like CD31 antibodies requires significant investments in technology and infrastructure, leading to high manufacturing costs, which can limit market access for smaller players.
Regulatory Barriers: Stringent regulatory requirements for the approval of therapeutic antibodies, including the necessity for comprehensive clinical trials, can delay market entry and increase costs.
Personalized Medicine: The rise of personalized medicine presents opportunities for CD31 antibodies, as these antibodies can be used to target specific cells and molecular pathways, improving treatment outcomes for patients.
Collaborations and Partnerships: Strategic collaborations between biotechnology companies and academic institutions are expected to drive innovation and accelerate the development of new antibody based diagnostics and treatments.
Advancements in biotechnology, particularly with the introduction of CRISPR and gene editing technologies, are significantly enhancing the efficacy of CD31 antibodies. Additionally, governments around the world are tightening regulations around antibody approvals, ensuring safety and efficacy for clinical applications. In terms of sustainability, the industry is focused on minimizing the environmental impact of antibody production through green chemistry initiatives and more efficient manufacturing processes.
Biomedical Research: The largest segment, CD31 antibodies are widely used in research to study vascular biology, angiogenesis, and immune response. They are essential in the study of endothelial cell function and are utilized in a variety of tissue studies.
Diagnostics: CD31 antibodies are commonly employed in diagnostic assays, particularly for detecting endothelial cell activation or injury, which is crucial in assessing diseases like atherosclerosis and thrombosis.
Therapeutics: With the growing focus on immunotherapy, CD31 antibodies are being explored as potential therapeutic agents for targeting endothelial cells in cancers, vascular diseases, and inflammatory conditions.
Research and Academic Institutions: These end users represent a significant share of the market as they conduct studies on vascular diseases, cancer, and other immunological disorders.
Pharmaceutical and Biotech Companies: These companies use CD31 antibodies in drug development processes, particularly in creating targeted therapies and diagnostic products.
Hospitals and Diagnostic Laboratories: CD31 antibodies are crucial for use in diagnostics to aid clinicians in assessing disease progression and treatment efficacy.
North America: Dominates the global market due to advanced healthcare infrastructure, significant research funding, and a high prevalence of cardiovascular diseases and cancer.
Europe: The second largest market, Europe benefits from strong healthcare systems, growing demand for personalized medicine, and active research in oncology and cardiovascular diseases.
Asia Pacific: Expected to experience the highest growth rate, driven by increasing healthcare investments, a rising aging population, and growing awareness about advanced diagnostic tools.
Several companies are currently leading the CD31 antibody market, including:
Thermo Fisher Scientific: A key player in the production of monoclonal antibodies, Thermo Fisher offers a range of CD31 antibodies for research applications, particularly in cancer and vascular biology.
Bio Rad Laboratories: Known for producing highly specific antibodies for diagnostic and therapeutic uses, Bio Rad has made significant contributions to the CD31 antibody market with its high quality product offerings.
Abcam: Abcam provides a diverse range of CD31 antibodies, widely used in both research and clinical settings. They are also active in collaborations to develop cutting edge antibody products.
Sigma Aldrich: Sigma Aldrich, a subsidiary of Merck, is a major player in the supply of research grade CD31 antibodies and continues to enhance its product offerings with innovative solutions in antibody technology.
Emerging trends in the CD31 antibody market include the development of monoclonal and polyclonal antibodies with enhanced specificity, as well as innovations in antibody drug conjugates ADCs that target specific vascular components in tumors. Another notable trend is the application of artificial intelligence AI and machine learning to improve the discovery and development processes of antibodies. Furthermore, biopharmaceutical companies are increasingly focusing on personalized immunotherapy, where CD31 antibodies play a crucial role in targeting disease specific biomarkers.
Supply Chain Issues: Raw materials for antibody production, such as animal sera, are often sourced globally. Supply chain disruptions can lead to delays and increased costs in antibody production.
Regulatory Challenges: The approval process for new antibody based therapies is lengthy and complex, requiring extensive preclinical and clinical testing.
Pricing Pressures: The high cost of developing CD31 antibodies may limit their affordability, especially in developing regions where healthcare budgets are constrained.
Supply Chain Diversification: Companies can mitigate supply chain risks by diversifying their supplier base and incorporating local production facilities.
Regulatory Streamlining: Increased collaboration between regulatory agencies and industry stakeholders can help expedite the approval process while maintaining safety standards.
Cost Reduction Strategies: Adoption of more efficient manufacturing processes, such as continuous flow production, and optimization of antibody yield can help reduce costs.
The CD31 antibody market is expected to experience sustained growth, driven by the expanding applications of monoclonal antibodies in diagnostics and therapeutics. The increasing focus on immunotherapy, coupled with the rise of personalized medicine, will propel demand for these antibodies. The market will also benefit from advancements in antibody production technologies, including recombinant antibody engineering and automation in manufacturing processes. However, regulatory hurdles and high production costs remain significant challenges that need to be addressed to ensure widespread adoption.
North America currently leads the market due to advanced healthcare infrastructure, followed by Europe and the Asia Pacific region, which is expected to experience the highest growth.
CD31 antibodies are primarily used in biomedical research, diagnostics, and therapeutics, particularly for studying endothelial cells, angiogenesis, and immune responses in diseases like cancer and cardiovascular conditions.
Key challenges include high production costs, regulatory approval barriers, and potential supply chain disruptions due to global sourcing of materials.
Major
BosterBio
Bio-Rad
Bioss
Thermo Fisher Scientific
NSJ Bioreagents
R and D Systems
Abcam
BioLegend
GeneTex
Novus Biologicals
SouthernBiotech
LifeSpan BioSciences
Enzo Life Sciences
Bethyl Laboratories
Abbexa
ProSci
Proteintech
Synaptic Systems
BIOCARE MEDICAL
CUSABIO Technology
Absolute Antibody
EpiGentek
Biorbyt
Wuhan Fine Biotech
Sino Biological
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the Global CD31 Antibody Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the Global CD31 Antibody Market
Immunochemistry (IHC)
Immunofluorescence (IF)
Western Blot (WB)
Immunocytochemistry (ICC)
ELISA
Others
Based on Types the Market is categorized into Below types that held the largest CD31 Antibody market share In 2023.
Monoclonal
Polyclonal
Global (United States, Global and Mexico)
Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
South America (Brazil, Argentina, Columbia, etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
For More Information or Query, Visit @ CD31 Antibody Market Research Analysis
1. Introduction of the Global CD31 Antibody Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. Global CD31 Antibody Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. Global CD31 Antibody Market, By Type
6. Global CD31 Antibody Market, By Application
7. Global CD31 Antibody Market, By Geography
Global
Europe
Asia Pacific
Rest of the World
8. Global CD31 Antibody Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading Global Research and Consulting firm servicing over 5000+ global clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/